Inclusion Criteria:

- Histologically confirmed adenocarcinoma that failed standard curative options and for
which no standard palliative options are required within the next 8weeks

- Advanced or metastatic disease

- Recurrent or unresectable disease

- Microscopic metastatic disease confirmed by surgical exploration allowed

- CEA expression by immunohistochemistry

- Circulating CEA greater than 5 ng/mL

- HLA phenotyping required

- HLA phenotyping must be repeated for patients who have undergone allogeneic bone
marrow transplantation

- No clinically symptomatic brain metastases

- Patients with brain metastases who have completed palliative radiotherapy and
have discontinued steroids are eligible

- Hormone receptor status:

- Not specified

- Male or female

- Performance status - ECOG 0-1

- WBC at least 3,000/mm^3

- Platelet count at least 100,000/mm^3

- Bilirubin less than 1.5 times upper limit of normal (ULN)

- AST and ALT less than 3 times ULN

- PT and PTT less than 1.5 times ULN (unless therapeutically anticoagulated)

- Creatinine less than 1.5 mg/dL

- Creatinine clearance greater than 60 mL/min

- Proteinuria or hematuria less than +2 on urinalysis*

- Urine protein less than 1,000 mg/24-hour collection, if proteinuria greater than +1

- No frequent vomiting or severe anorexia

- No more than 10% weight loss within the past 3 months

- No inflammatory bowel disease, Crohn's disease, ulcerative colitis, or active
diverticulitis

- No uncontrolled seizure disorders

- No encephalitis

- No multiple sclerosis

- No allergy to eggs

- No HIV-associated opportunistic infection

- No autoimmune diseases, including the following:

- Systemic lupus erythematosus

- Sjögren's syndrome

- Scleroderma

- Myasthenia gravis

- Goodpasture syndrome

- Addison's disease

- Hashimoto's thyroiditis

- Graves' disease

- Antinuclear antibody positive status allowed if no evidence of an autoimmune disease

- No direct contact of vaccination site with the following persons for at least 72
hours after each vaccination:

- Children under 1 year of age

- Pregnant women

- Individuals with eczema or other open skin condition

- Immunocompromised individuals

- No other concurrent serious medical illness that would preclude study entry

- No other malignancy within the past 2 years except excised basal cell or squamous
cell skin cancer or carcinoma in situ of the cervix

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception for at least 1 month before (female
patients only), during, and for at least 3 months after study participation

- See Disease Characteristics

- No prior CEA-directed active immunotherapy

- Prior CEA-directed antibody therapy allowed

- At least 4 weeks since prior immunotherapy and recovered

- No other concurrent antineoplastic biologic therapy or immunotherapy

- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and
recovered

- No concurrent antineoplastic chemotherapy

- See Disease Characteristics

- No concurrent antineoplastic hormonal therapy

- No concurrent systemic steroids (inhaled steroids allowed)

- Concurrent systemic mineralocorticoids (e.g., megestrol for appetite stimulation or
fludrocortisone) allowed

- Concurrent birth control pills allowed

- See Disease Characteristics

- At least 4 weeks since prior radiotherapy and recovered

- No prior radiotherapy to more than 50% of all nodal groups

- See Disease Characteristics

- Recovered from prior surgery

- No prior splenectomy

- Concurrent non-steroidal anti-inflammatory drugs allowed

- No other concurrent anti-cancer therapy